Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.
- Injectable quetiapine reformulation targets >US$2B delirium market
- Accelerated FDA 505(b)(2) pathway with 3–5 year timeline
- Proprietary patent protection extends to ~2042
- Phase 1A trial initiation planned for Q3 2026
- Significantly lower development cost (~$20–30M) versus new drugs
Injectable Quetiapine Targets Unmet Delirium Market
Patrys Limited (ASX:PAB) is advancing a reformulated injectable version of quetiapine designed to address the substantial unmet need in delirium treatment, a market estimated at over US$2 billion annually. Unlike current off-label oral treatments, the new formulation promises rapid onset suitable for ICU, palliative, and aged care settings, potentially improving patient outcomes and reducing hospital stays.
Delirium affects up to 80% of ICU patients and presents as severe acute brain dysfunction with symptoms ranging from confusion to aggressive behaviour. Current pharmacological options, including oral quetiapine, haloperidol, and benzodiazepines, are used off-label and suffer from slow onset, administration challenges, and significant side effects. Patrys’ injectable quetiapine aims to overcome these limitations by delivering faster therapeutic effects and an improved safety profile.
Accelerated Development with Strong Intellectual Property
Patrys is leveraging the FDA’s 505(b)(2) regulatory pathway, which allows reliance on existing safety and efficacy data for quetiapine, substantially shortening the development timeline to 3–5 years and slashing costs to an estimated $20–30 million compared to the billion-dollar price tag for novel drug development. This pathway reduces regulatory and clinical risks, focusing on bridging studies to confirm dosing and safety for the injectable formulation.
The company holds a provisional patent application filed in 2026, covering the new formulation composition, method of use for delirium, and delivery system, with patent protection expected to extend to approximately 2042. Patrys highlights the technical complexity of its formulation as a strong barrier against competition, complementing the accelerated approval strategy.
Clinical Milestones and Development Timeline
Patrys plans to initiate its Phase 1A clinical trial of the injectable quetiapine in healthy volunteers by Q3 2026, pending ethics approval, with Phase 1B trials in ICU delirium patients targeted for 2027. These studies will assess pharmacokinetics, safety, and preliminary efficacy, building on decades of clinical data from oral quetiapine use. The company anticipates a global pivotal ICU delirium study in 2028, which could pave the way for regulatory approval and potential partnering opportunities.
This development timeline is supported by recent manufacturing milestones and regulatory preparations, positioning Patrys to deliver clinical data within the next 18–24 months. The capital-efficient approach reflects a structurally de-risked opportunity with no manufacturing scale-up required and a clear path to reimbursement supported by established efficacy profiles.
Corporate Positioning and Market Opportunity
With a market capitalisation around $25.6 million and a cash balance of $3.36 million as of July 2026, Patrys is navigating a pivotal phase in its injectable quetiapine program. The company’s executive team combines expertise in biotech commercialisation, clinical trials, and capital markets, providing a solid foundation for progressing this asset.
Patrys’ reformulation strategy aligns with recent FDA approvals of similar oral-to-injectable transitions, underscoring the commercial viability of this approach. The injectable quetiapine’s potential to reduce ICU stays and improve delirium management could translate into significant healthcare cost savings and better patient outcomes, addressing a clear gap in current treatment options.
Bottom Line?
Patrys’ injectable quetiapine program offers a compelling, de-risked path to market with clear clinical advantages and strong IP, but clinical trial execution and regulatory milestones over the next two years will be critical to validate its commercial potential.
Questions in the middle?
- Will Phase 1B safety and feasibility data in ICU patients confirm the expected benefits of the injectable formulation?
- How will Patrys position itself for partnering or licensing ahead of pivotal Phase 3 trials?
- Can the company maintain sufficient cash runway to reach key clinical milestones without dilutive capital raises?